Pharmacology

Introduction

The development of a cutting edge research programme in pharmacology is an essential part of our research strategy, where we are focussing on areas such as malignant disease, inflammation and chemotherapy-induced emetogenesis.  These areas are far reaching clinically, and impact upon the treatment of cancer with chemotherapy and the many diseases where inflammation is an important aspect of their cause, such as asthma, arthritis and inflammatory bowel disease.  These therapeutic areas all have one thing in common; changes in metabolism, where investigation of the complex processes involved in metabolism and how they go wrong in disease will be a vital part of our work. We see pharmacology as an essential component of medicines research and an important bridge between the biological sciences and medicinal chemistry. Expansion and investment in both classical and molecular pharmacology expertise within the division will enable us to reveal new targets that act as templates for the design of novel drugs. We also aim to develop realistic and clinically relevant models of disease from which we can gain much knowledge of how the disease works and the effectiveness of the medicines we use to treat them.